1Li LS,Liu ZH. Epidemiologic data of renal diseases from a single unit in China:analysis based on 13,519 renal biopsies. Kidney Int, 2004, 66 ( 3 ) :920 - 923.
2Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program,2010,2010:287 - 294.
3Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol, 1995, 32 (1) :45 -59.
4Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis:prognostic value and correlations with clinical features. Blood, 2010, 116 (24) :5126 -5129.
5Merlini G, Bellotti V. Molecular mechanisms of amyioidosis. N Engl J Med,2003,349(6) :583 -596.
6Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem, 2009,55 ( 3 ) :499 - 504.
7Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol,2011,29(14) :1924- 1933.
8Gillmore JD, Lachmann HJ, Rowczenio D, et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol, 2009,20 ( 2 ) :444 - 451.
9Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood,2012,119 ( 8 ) : 1844 - 1847.
10Schonland SO, Dreger P, de Witte T, et al. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant, 2012, 47 (7) :895 - 905.
